Astel­las de­tails po­ten­tial rea­son be­hind deaths in rare dis­ease gene ther­a­py tri­al

Four boys with a rare and of­ten se­vere ge­net­ic mus­cle dis­ease died in 2020 and 2021 af­ter re­ceiv­ing a one-time gene ther­a­py from Astel­las Phar­ma, and a new study seeks to ex­plain what caused their deaths.

In the study pub­lished Wednes­day in Lancet Neu­rol­o­gy, re­searchers de­tailed a po­ten­tial ex­pla­na­tion for the liv­er tox­i­c­i­ty that led to the deaths of the four boys and de­pict­ed the strik­ing ben­e­fits of the X-linked my­otubu­lar my­opa­thy (XLMTM) gene ther­a­py in the 20 chil­dren who sur­vived.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER